Index of drugs

Treatment of increased intraocular pressure in patients with: ocular hypertension, chronic open-angle glaucoma.

1 ml of solution contains 5 mg of Timolol in the form of maleate. The preparation contains benzalkonium chloride.

Non-selective β-blocker, not showing significant intrinsic sympathomimetic activity, direct inhibitory effect on the myocardium or local anesthetic effect. The mechanism of action may be associated with a reduction in the amount of aqueous humor produced. After topical application, it starts to work quickly, after about 20 minutes, the maximum effect occurs after about 1-2 hours and lasts for 24 hours.

Hypersensitivity to the active substance or to any of the excipients. Airway hyperreactivity, bronchial asthma currently or in history, severe chronic obstructive pulmonary disease. Sinus bradycardia, sinoatrial block, atrio-ventricular block IIst. or third-century, overt cardiac failure, cardiogenic shock.

Use in children is not recommended. During treatment with β-adrenergic receptor inhibitors, patients with atopic disease or severe anaphylactic reactions to a variety of allergens may have an increased response to reacting with these allergens again. The preparation contains benzalkonium chloride, may cause eye irritation. Avoid contact of the preparation with soft contact lenses.

The preparation can be used during pregnancy only if the potential benefit to the mother outweighs the potential risk to the fetus. Timolol may cause serious adverse reactions in breastfed infants, therefore, taking into account the importance of using the drug for the health of the mother, consider whether to stop breast-feeding or stop the use of the drug.

The following were observed: eye irritation (burning, prickling), conjunctivitis, blepharitis, keratitis, decreased corneal sensitivity, dry eye, visual disturbances (including refraction disorders), double vision, ptosis, choroidal dissection after filtration; ear noise; slow heart rate, arrhythmia, low blood pressure, fainting, heart block, cerebral stroke, cerebral ischemia, congestive heart failure, palpitations, cardiac arrest, edema, claudication, Reynaud's symptom, cold hands and feet, chest pain; bronchospasm, respiratory failure, shortness of breath, cough; alopecia, psoriasis-like rash or exacerbation of psoriasis; signs and symptoms of allergic reactions (including anaphylaxis, angioneurotic edema, urticaria, local or systemic erythema, systemic lupus erythematosus); headache, dizziness, depression, insomnia, nightmares, memory loss, worsening symptoms and symptoms of myasthenia gravis, paresthesia, decreased libido, cerebrovascular accident; nausea, diarrhea, digestive disorders, dry mouth; Peyronie's disease; weakness, tiredness; anorexia; symptoms from o.u.n. (eg behavioral disorders, including confusion, hallucinations, anxiety, confusion, nervousness, drowsiness); macular cystic edema in patients with no lens; hypertension; nasal congestion, retroperitoneal fibrosis, pseudopemphigoid.

Usually, treatment is started by administering 1 drop of 0.25% timolol maleate to each affected eye twice a day. If you do not get the right treatment result, you can change the dosage and administer 1 drop of 0.5% solution of timolol maleate to each affected eye twice a day. In order to lower intraocular pressure, the preparation can be used simultaneously with other medicines. However, simultaneous topical administration of two β-adrenergic receptor inhibitors is not indicated. Due to the fact that in some patients stabilization of intraocular pressure occurs only after several weeks of treatment, the evaluation of the effect of the preparation should be based on intraocular pressure measurements after approximately 4 weeks of use.In many cases, if the intraocular pressure stabilizes, the dose can be reduced by using it once a day. Absorption of the active substance into the body can be limited by compressing the nasolabial tracts or closing the eyelids for 2 minutes. This can help to strengthen local action.Change in the current method of treatment. If the patient previously used a different β-adrenergic receptor in the form of eye drops, the usual dose should be administered on the last day of its use. The Next day, apply a 0.25% solution of timolol maleate to each affected eye twice daily. If the treatment is not satisfactory, you can increase the dose to 1 drop of 0.5% of the solution in each affected eye twice a day. If the patient previously used one anti-UV agent, which is not an inhibitor of β-adrenergic receptors, one should still add 1 drop of 0.25% solution of timolol maleate to each affected eye twice a day. On the next day, the previously used anti-glaucoma should be discontinued and treatment should be continued with 0.25% timolol maleate. If a larger dose is required, apply 1 drop of 0.5% timolol maleate to each affected eye twice a day.